Evidence map›Paper›PMID 38259634›Full record

ArticleFrontiers in global women's health2023

Feasibility and acceptability of an HPV self-testing strategy: lessons from a research context to assess for ability to implement into primary care at a national level in Botswana.

Rebecca Luckett, Doreen Ramogola-Masire, Devon A Harris, Annika Gompers, Kelebogile Gaborone, Lorato Mochoba, Lapelo Ntshese, Anikie Mathoma, Maduke Kula, Roger Shapiro and 1 more

Abstract read
In one paragraph

Article in Frontiers in global women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rebecca Luckett *Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Doreen Ramogola-Masire *Department of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana.
Devon A HarrisDepartment of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Annika GompersDepartment of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Kelebogile GaboroneBotswana Harvard Health Partnership, Gaborone, Botswana.
Lorato MochobaBotswana Harvard Health Partnership, Gaborone, Botswana.
Lapelo NtsheseDepartment of Obstetrics and Gynaecology, Bamalete Lutheran Hospital, Ramotswa, Botswana.
Anikie MathomaDepartment of Obstetrics and Gynecology, University of Botswana, Gaborone, Botswana.
Maduke KulaNational Cervical Cancer Prevention Program, Ministry of Health and Wellness Botswana, Gaborone, Botswana.
Roger ShapiroBotswana Harvard Health Partnership, Gaborone, Botswana.
Elysia LarsonDepartment of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.

Funding

Evaluation of triage strategies and screening intervals in a human papillomavirus based cervical cancer screening program in women living with human immunodeficiency virus in BotswanaK08CA271949 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Rebecca Luckett · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA271949
6 · The paper itself

Abstract

Background: The WHO strategy for cervical cancer elimination strives to achieve 70% coverage with high-performance cervical screening. While few low- and middle-income countries have achieved this, high-risk human papillomavirus (hrHPV) self-testing creates the possibility to rapidly upscale access to high-performance cervical screening across resource settings. However, effective hrHPV screening requires linkage to follow-up, which has been variable in prior studies. This study developed and tested an implementation strategy aimed at improving screening and linkage to follow-up care in South East District in Botswana. Methods: This study performed primary hrHPV self-testing; those with positive results were referred for a triage visit. Withdrawals for any reason, loss-to follow-up between hrHPV test and triage visit, and number of call attempts to give hrHPV results were also documented. Acceptability of the program to patients was measured as the proportion of patients who completed a triage visit when indicated, meeting the Results: Enrollment of 3,000 women occurred from February 2021 to August 2022. In total, 10 participants withdrew and an additional 33 were determined ineligible after consent, leaving a final cohort of 2,957 participants who underwent self-swab hrHPV testing. Half (50%) of participants tested positive for hrHPV and nearly all (98%) of participants received their hrHPV results, primarily via telephone.  Few calls to participants were required to communicate results: 2,397 (82%) required one call, 386 (13%) required 2 calls, and only 151 (5%) required 3-5 calls. The median time from specimen collection to participant receiving results was 44 days (IQR, 27-65). Of all hrHPV positive participants, 1,328 (90%) attended a triage visit. Discussion: In a large cohort we had low loss-to-follow-up of 10%, indicating that the strategy is acceptable. Telephonic results reporting was associated with high screening completion, required few calls to participants, and supports the feasibility of hrHPV self-testing in primary care followed by interval triage.

Indexed as

acceptabilitycervical cancer screeningfeasibilityHPV testing implementationhuman papillomavirus (HPV)low-and middle-income countries (LMICs)

Identifiers

PMID38259634
PMCPMC10800890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.